Concentra Reports Q4 Revenue of $539.1M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1d ago
0mins
Reports preliminary Q4 revenue $539.1M, consensus $532M. "The 2025 fiscal year was another transformative year for Concentra as we continued to provide superior outcomes and exceptional experience to our patients and customers, all while significantly growing our business," said Keith Newton, Concentra's Chief Executive Officer. "Our excellent performance in 2025 is a testament to our skilled and dedicated colleagues' efforts to improve the health of America's workforce, one patient at a time."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CON?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CON
Wall Street analysts forecast CON stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CON is 28.67 USD with a low forecast of 27.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 21.600
Low
27.00
Averages
28.67
High
30.00
Current: 21.600
Low
27.00
Averages
28.67
High
30.00
About CON
Concentra Group Holdings Parent, Inc. is a provider of occupational health services in the United States. It delivers an extensive suite of services, including occupational and consumer health services and other direct-to-employer care, to more than 50,000 patients each day, on average, from about 620 occupational health centers in 41 states and 160 onsite health clinics at employer worksites in 36 states. Its Occupational Health Centers segment encompasses the services it delivers at its occupational health center facilities across the United States. Its Onsite Health Clinics segment delivers occupational health services and/or employer-sponsored primary care services at an employer’s workplace, including mobile health services and episodic specialty testing services. Its Other Businesses segment comprises several complementary services to its core occupational health services offering and includes Concentra Telemed, Concentra Pharmacy and Concentra Medical Compliance Administration.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Concentra Releases Preliminary Financial Results for FY 2025
- Significant Revenue Growth: For FY 2025, Concentra expects revenue to reach $2.1634 billion, a 13.9% increase from $1.9002 billion in FY 2024, indicating strong market demand and business expansion capabilities in the occupational health services sector.
- Substantial Net Income Increase: The anticipated net income for FY 2025 is $172.8 million, slightly up from $171.9 million in FY 2024, reflecting ongoing improvements in cost control and operational efficiency.
- Record Patient Visits: In FY 2025, patient visits are projected to total 13,546,707, averaging 53,124 visits per day, which is a 7.7% increase from 49,311 visits per day in FY 2024, demonstrating success in enhancing customer service and market penetration.
- Optimistic 2026 Outlook: Concentra forecasts revenue for 2026 to be between $2.25 billion and $2.35 billion, with adjusted EBITDA expected to be between $450 million and $470 million, showcasing confidence in future growth and effective strategic planning.
Continue Reading
Continental Meets Full-Year Sales Targets, Advances ContiTech Sale
- Sales Performance Achieved: Continental reported approximately €19.7 billion in sales for fiscal 2025, aligning with its guidance range of €19.5 billion to €21 billion, demonstrating stability despite market challenges.
- Strong Tyres Division: The tyres business generated around €3.6 billion in sales for Q4, with full-year sales expected at €13.8 billion and an adjusted EBIT margin projected at 13.6%, reflecting positive mix effects and cost optimizations.
- ContiTech Challenges: Despite overall strong performance, ContiTech's profitability fell short of expectations, with Q4 sales anticipated at around €1.4 billion and full-year sales at approximately €6 billion, indicating a persistently weak market environment.
- Sale Plan Progressing: Continental is advancing its plan to divest ContiTech by 2026, having completed internal preparations and concluded the market outreach phase, with a structured sales process set to begin this month, indicating strong market interest in the division's value.
Continue Reading